Atrial Fibrillation: Screening

1. Randomized trials enrolling asymptomatic persons that directly compare screening with usual care and that assess both health outcomes and harms. It is important that screening trials enroll sufficient participants of both sexes and diverse racial and ethnic groups to enable assessment of whether the detection of atrial fibrillation (AF), or the benefits or harms of screening, vary in different population groups.
2. How to best optimize the accuracy of screening tests or strategies for AF.
3. Understanding the risk of stroke associated with subclinical AF, or AF detected with use of consumer devices, how that risk varies with duration or burden of AF, and the potential benefit of anticoagulation therapy among persons with subclinical AF.

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for atrial fibrillation among asymptomatic adults 50 years or older.

Atrial Fibrillation: Screening Read full statement 1 U.S. Preventive Services Task Force